Dr. Herman Weiss
Oct 16, 2026
Welcome back to The Pause Collective Science Review, where I read the science so you don't have to. Most days the literature is a slow drip. This was not one of those weeks: America's ob-gyn college published its most comprehensive menopause guidance to date, and the PMOS literature delivered two papers that speak directly to where those women are heading in midlife. Five papers, annotated and referenced, plus what is trending.
1. ACOG finally weighs in, properly: a full guideline for hot flashes, sleep, and mood
Two weeks ago in Issue 8 we reviewed the American College of Physicians' new guideline on vasomotor symptoms. Now the American College of Obstetricians and Gynecologists has published Clinical Practice Guideline No. 13 - its most complete menopause guidance to date - covering vasomotor symptoms (hot flashes and night sweats), sleep disruption, and mood changes, in both spontaneous and induced menopause.
What it says: hormone therapy is an important tool, and starting it should be a shared decision based on symptoms, age, medical history, and baseline cardiovascular, breast cancer, and clotting risk. If chosen, ACOG recommends starting before age 60 or within 10 years of menopause in women without contraindications - the timing hypothesis I have written about here more than once. For women who cannot or prefer not to use hormones, the guideline reviews nonhormonal medications, including the neurokinin receptor antagonists fezolinetant and elinzanetant, plus SSRIs and SNRIs that can serve both hot flashes and depression. Non-drug options - cognitive behavioral therapy, mindfulness-based approaches, exercise, clinical hypnosis, acupuncture - get evidence-based recommendations too, usually as complements. It also calls for earlier patient education, and a companion guideline on genitourinary syndrome is promised for 2027.
The context behind it is sobering: 50-92% of women report vasomotor symptoms, 16-66% report menopause-related sleep disruption, and more than a third report depressive symptoms. ACOG's president framed the release explicitly against menopause misinformation.
My take: this matters less for any single recommendation - most mirror what the Menopause Society already says - and more for who is saying it. ACOG is the home institution of the generalists who see the most women, and it is pairing the guideline with a full menopause special issue of its journal. Guidelines do not change practice overnight, but they change what insurance covers and what clinicians feel permitted to offer. The limits: this is a guideline, not new data, and its recommendations are only as strong as the underlying trials, several of which (acupuncture, hypnosis) rest on modest evidence.
Citation: American College of Obstetricians and Gynecologists. Clinical Practice Guideline No. 13: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. Obstet Gynecol, 2026 (November issue; published October 15). doi:10.1097/AOG.0000000000006428.
2. Menopause before 40 nudges diabetes risk up - and hormones change the picture
The Women's Health Initiative keeps giving. Researchers followed 136,759 postmenopausal women aged 50-70 and asked whether premature menopause (before age 40, experienced by 9.7% of the cohort) predicts type 2 diabetes later.
What they found: a modest but real signal. Women with premature menopause had about a 10% higher relative risk of developing diabetes (hazard ratio 1.10, 95% CI 1.05-1.16) compared with women reaching menopause at 50-54. The detail I find most interesting: hormone therapy modified the risk. Among women with natural premature menopause, the elevated risk appeared in those who never used hormone therapy (HR 1.24) and those who used estrogen-plus-progestogen (HR 1.35), but not in estrogen-only users. And BMI explained roughly 28% of the association - body weight is a meaningful part of the mechanism, not the whole story.
In plain English: losing ovarian function early costs you some metabolic protection, and the hormone story is not simple - estrogen alone looked neutral here, while the combination did not. Limits: menopause timing was self-reported, diabetes was defined by treatment initiation, and this is observational - no causation claims. For my PMOS readers: your risk story runs the opposite direction in one sense (many of you will reach menopause later), but the shared lesson is that ovarian hormones and metabolic health are entangled for decades, and weight management is leverage you actually hold.
Citation: Du Y, LeBlanc ES, Shadyab AH, Liu L, Banack HR, Wild RA, Saquib N, Spracklen CN. Premature menopause and risk of type 2 diabetes among postmenopausal women: findings from the Women's Health Initiative. Menopause, 2026 (published October 13). doi:10.1097/GME.0000000000002907.
3. Depression before menopause flags heart risk after it
A large real-world study using the TriNetX network matched 88,884 postmenopausal women who had been diagnosed with depression before menopause against 88,884 similar women who had not - excluding anyone with existing cardiovascular disease or conventional risk factors like smoking, diabetes, hypertension, or obesity.
What they found: over up to 20 years of follow-up, 4.0% of the premenopausal-depression group developed cardiovascular disease versus 3.3% of controls - a relative risk of 1.23 (95% CI 1.17-1.29). The absolute difference is small, about 7 extra cases per 1,000 women, but the cohort is enormous and the matching careful.
In plain English: depression in your 30s and 40s is not only a mental-health diagnosis - it is a midlife cardiovascular risk marker worth writing on your chart, the way we already treat family history. It does not mean depression causes heart disease; the study cannot say that. But it means a woman with that history deserves earlier, more deliberate cardiovascular prevention conversations. For PMOS readers: depression and anxiety rates run high in PMOS, so this cohort finding is doubly relevant - mood care is heart care, starting long before menopause. Limits: retrospective, database-based, and the proportional-hazards assumption failed, so treat the hazard ratio as an average, not a constant risk.
Citation: Raju P, Jiang LF, Kutty A, Nudy M. Premenopausal depression and risk of cardiovascular disease after menopause: a large real-world cohort study. Cardiology, 2026 (published October 15). doi:10.1159/crd/absag025.
4. A liver drug finally tested in the women who need it: saroglitazar in PMOS with fatty liver
Here is a gap I have complained about before: women with PMOS have high rates of fatty liver disease (MASLD), yet they are systematically underrepresented in liver drug trials. This multicenter, double-blind, placebo-controlled phase 2A trial randomized 60 women aged 18-45 with PMOS and MASLD to saroglitazar 4 mg (a dual PPAR-alpha/gamma agonist) or placebo for 24 weeks.
What they found: liver fat (measured by MRI-PDFF, the proper way) fell about 15% relative to baseline in the treatment group versus a slight rise on placebo (p=0.041); adjusted for a baseline HbA1c imbalance, the gap widened. More than a third of treated women (36%) achieved at least a 30% liver-fat reduction versus 8.7% on placebo, and liver enzymes, lipids, and fibrosis-risk scores improved too. Side effects were comparable between groups, none serious.
In plain English: this is early-phase and small, but it is the right drug class (metabolic, insulin-sensitizing) tested in the right population for once. Saroglitazar is already used in India for diabetic dyslipidemia; this trial makes a case for a dedicated PMOS-liver indication. And for readers heading toward perimenopause with a PMOS history: liver fat tends to rise in the menopause transition, so having therapies tested in your phenotype matters for the decades ahead. Limits: 60 women, 24 weeks, per-protocol analysis - promising, not practice-changing yet.
Citation: Samala N, Gonzalez-Gonzalez J, Jenders R, Sarkar M, Reza R, Rodas F, Kipnes M, Gonzalez EM. Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: a multicenter, double-blind, placebo-controlled study. Hepatology, 2026 (published October 15). doi:10.1097/HEP.0000000000001862. Trial NCT03617263.
5. PMOS and the aging brain: what we actually know about the Alzheimer's link
You may have seen headlines this week linking PMOS to dementia (the Endocrine Society issued a press release, and Newsweek ran the story). The source is this new comprehensive review in the Journal of the Endocrine Society, led by Ricardo Azziz's group - the same team behind the PMOS renaming effort - surveying everything published through October 2025 on cognition, brain imaging, biomarkers, and dementia risk in PMOS.
What it found: plausible mechanisms exist (insulin resistance, chronic inflammation, hormonal dysregulation, cardiovascular dysfunction, all converging on amyloid and tau biology), and women with PMOS show mild but reproducible deficits in executive function and memory plus subtle imaging changes. But - and this is the part the headlines underplay - direct epidemiological evidence that PMOS independently raises dementia incidence is limited and inconsistent. The association, where it exists, appears largely mediated by metabolic comorbidities, particularly insulin resistance and obesity, not by PMOS itself. No PMOS-specific intervention has yet shown cognitive benefit.
In plain English: the honest summary is "reason to manage your metabolism, not reason to panic." This is exactly the cross-education point I make to both audiences: the same insulin-resistance-and-inflammation machinery that drives midlife cardiovascular risk in PMOS is what we watch in brain aging after menopause. Manage the metabolism and you are already doing the brain-protection work. Limits: this is a narrative review of heterogeneous studies, not new data.
Citation: Amiri M, Kakavand Hamidi A, Farkas DL, Buyalos RP, Azziz R. Potential links between PCOS/PMOS and Alzheimer disease and related dementias. J Endocr Soc, 2026 (November issue; press coverage October 13-14). doi:10.1210/jendso/bvag206.
Cross-references (covered elsewhere, one line each): the ACP vasomotor-symptom guideline was fully reviewed in Issue 8 (October 7). The metformin-before-IVF cohort got Post #10 (October 7), and this week's Journal of Gynecology paper on metformin plus myo-inositol for fertility in PMOS sits close enough to it that I am noting rather than re-reviewing it. The soy/isoflavone umbrella review for cholesterol after menopause became this week's single-study post (#12, published today).
WHAT'S TRENDING
Grounded in coverage I could actually read this week (news outlets and society press releases); I did not browse TikTok or Reddit directly this cycle, so platform-specific sentiment below is inference from what is getting amplified, and I say so.
The ACOG guideline dominated the professional feed within hours (ACOG newsroom, Healio, Contemporary OB/GYN, Endocrinology Advisor, October 15). Expect it to be the talk of the Menopause Society Annual Meeting, which opens October 20 in San Diego. Watch for the usual distortion: "ACOG says every woman should take hormones." It does not say that - it says individualized, shared decisions, before 60 or within 10 years.
UK HRT shortage warnings resurfaced (BBC, October 14) - a new geography on a story we tracked in Spain and Europe in Issue 9. Shortages push women toward unregulated substitutes; if your product is unavailable, the answer is a pharmacist-supervised switch, not a marketplace.
Testosterone-for-menopause skepticism got a well-reported expert piece (Live Science, October 15: "No one studied the safety"). This matches what I wrote in Post #8 - the cognition evidence is thin and the marketing is ahead of the data. The pendulum of the conversation is swinging from hype toward scrutiny, which is healthy.
PMOS had a mainstream media week: the Alzheimer's-link review above was amplified by the Endocrine Society (October 13) and Newsweek (October 14), and ABC News ran a "PCOS gets a new name" explainer (October 14) - the rename story reaching general-audience US television coverage is new. My read: the name is now in the adoption phase we tracked in Issues 8 and 9.
In supplement marketing, a postbiotic Akkermansia product is being promoted to the PMOS community with metabolic and endocrine claims (trade press, this week). The underlying science on Akkermansia is genuinely interesting and genuinely early - mouse-to-human translation is where good intentions go to die. No PMOS-specific trials behind the marketing that I could find.
Until the next one,
Dr. Herman Weiss
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health-care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here. Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.